Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT06048926 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06048926
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- ENROLLING_BY_INVITATION
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-30
- Primary completion
- 2025-07-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.